Atyr Pharma INC Form 4 insider transactions

Director Paul Schimmel purchased 100,000 shares of aTyr Pharma, Inc. common stock at a weighted average price of $0.4963.

ATYR Pharma reports that Director Timothy Coughlin acquired 50,000 stock options with an exercise price of $0.95, vesting in full on May 11, 2027, or the 2027 Annual Meeting.

Eric Benevich, a Director at ATYR Pharma Inc., has acquired 50,000 stock options, signaling a potential long-term commitment to the company.

Jane A. Gross, a Director at ATYR Pharma Inc., acquired 50,000 stock options with an exercise price of $0.95.

Svetlana Lucas, a Director at ATYR Pharma Inc., acquired 50,000 stock options with an exercise price of $0.95.

ATYR Pharma director Sara Zaknoen acquired 50,000 stock options with an exercise price of $0.95, vesting in full on May 11, 2027, or the 2027 Annual Meeting.

Paul Schimmel, a Director at ATYR Pharma Inc., acquired 50,000 stock options with an exercise price of $0.95, vesting in full on May 11, 2027, or the 2027 Annual Meeting.

aTyr Pharma's President and CEO, Sanjay Shukla, reported the vesting of 10,375 restricted stock units and a subsequent sale of 3,745 shares to cover tax obligations.

aTyr Pharma's CFO, Jill Marie Broadfoot, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

aTYR PHARMA's General Counsel, Nancy Denyes, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

aTYR Pharma's President and CEO, Sanjay Shukla, was granted 1.5 million employee stock options with an exercise price of $0.7127, vesting over three years.

aTyr Pharma's Chief Financial Officer, Jill Marie Broadfoot, was granted 412,500 employee stock options with an exercise price of $0.7127, vesting over three years.

aTYR Pharma's General Counsel, Nancy Denyes, was granted 412,500 employee stock options with a $0.7127 exercise price, vesting over three years.

Paul Schimmel, a Director at aTYR PHARMA INC, significantly increased his beneficial ownership by purchasing over 1 million shares of common stock.

Director Sara Zaknoen acquired 50,000 stock options in aTyr Pharma on May 1, 2025, according to a Form 4 filing.

Director Paul Schimmel acquired 50,000 stock options in aTyr Pharma, Inc. on May 1, 2025, according to a recent SEC filing.

Director Svetlana Lucas acquired 50,000 stock options in aTyr Pharma, Inc. on May 1, 2025, according to a Form 4 filing.

Director Jane A. Gross acquired 50,000 stock options in aTyr Pharma Inc. on May 1, 2025, according to a Form 4 filing.

Director Eric Benevich acquired 50,000 stock options in aTyr Pharma, according to a recent SEC Form 4 filing.

Director Timothy Coughlin acquired 50,000 stock options in aTyr Pharma, Inc. on May 1, 2025, according to a Form 4 filing.

Director Jane A. Gross reports the acquisition and disposal of aTyr Pharma Inc. common stock on March 17, 2025.

Sanjay Shukla, President and CEO of aTyr Pharma, reports the vesting of restricted stock units and subsequent acquisition of common stock.

Jill Marie Broadfoot, CFO of aTyr Pharma, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Nancy Denyes, General Counsel of aTyr Pharma Inc., sold 899 shares of common stock to cover tax obligations following the vesting of restricted stock units (RSUs).

aTyr Pharma's CEO, Sanjay Shukla, was granted 1 million stock options with a vesting schedule starting February 8, 2025.

Jill Marie Broadfoot, CFO of aTyr Pharma, acquired 275,000 employee stock options on January 8, 2025, according to a Form 4 filing.

Nancy Denyes, General Counsel of aTyr Pharma Inc., reports acquisition of stock options.

Director Eric Benevich of aTyr Pharma acquired 100,000 stock options on December 10, 2024, which vest over a three-year period.

Director Paul Schimmel reports acquiring additional shares of aTyr Pharma (ATYR) through a series of transactions, increasing his indirect holdings.

Nancy Denyes, General Counsel of aTyr Pharma, recently purchased 5,000 shares of the company's common stock at an average price of $1.8552 per share.